No Data
002727 Yixintang Pharmaceutical
Watchlist- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About Yixintang Pharmaceutical Company
The company was founded on November 8, 2000. Since its establishment more than 20 years ago, it has been deeply involved in Yunnan and spread throughout the country. As of March 31, 2023, Yixintang and its wholly-owned subsidiaries have a total of 9344 directly-managed chain stores, covering 10 provinces and municipalities directly under the Central Government, including Dian, Qian, Gui, Qiong, Sichuan, Chongqing, Jin, and Shanghai. It is a well-known and large-scale listed pharmaceutical retail chain enterprise in the country. At all times, Yixintang has upheld the service tenet of “serving the people with all our heart, serving the people wholeheartedly”, and insists on serving every consumer with “love, care, sincerity, care, and perseverance”. There are more than 30 million active members all over the world. The company's main business is the pharmaceutical retail chain and pharmaceutical distribution business. Among them, the pharmaceutical retail chain is the company's core business, mainly Chinese and Western proprietary medicines, followed by traditional Chinese medicine, medical devices, health products, and other personal care and beauty services. The company's honors include 2007 China's Top 100 Pharmaceutical Commercial Enterprises, 2014 China's Top 10 Pharmaceutical Chain Pharmacy Enterprises, 2018 China Pharmaceutical Retail Enterprise Innovation Champion, 2018 China Pharmaceutical Retail Enterprise Innovation Champion, 2018 National Top 100 Private Pharmaceutical Commercial Distribution Enterprise List, Pharmaceutical Supply Chain Logistics Best Service Provider, and 2019 Top 20 Main Business Revenue.
News
Yixintang (002727): Improving Profitability and Integrating Development of Multiple Business Models
Incident: In the first half of '23, the company achieved operating income of 8.676 billion yuan (+8.92%), net profit of 505 million yuan (+20.64%), net profit of 505 million yuan (+26.94%) after deducting non-return net profit of 505 million yuan (+26.94%);
Yixintang (002727): Profitability increased steadily in the first half of the year, and the number of stores continued to expand
Incident Isshintang released the 2023 semi-annual report. In the first half of 2023, the company achieved operating income of 8.676 billion yuan, +8.92% year on year; net profit to parent was 505 million yuan, +20.64% year on year;
Yixintang (002727) 2023 Interim Report Review: Steady Growth in Performance, Focus on Chronic Disease Management
Matters: Recently, the company released its 2023 annual report. 2023H1 achieved operating income of 8.676 billion yuan (YOY +8.92%), net profit of 505 million yuan (YOY +20.64%), and return to parent